Savara Inc
NASDAQ:SVRA
Savara Inc
Total Current Liabilities
Savara Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Savara Inc
NASDAQ:SVRA
|
Total Current Liabilities
$12.8m
|
CAGR 3-Years
6%
|
CAGR 5-Years
9%
|
CAGR 10-Years
5%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$38.7B
|
CAGR 3-Years
3%
|
CAGR 5-Years
20%
|
CAGR 10-Years
13%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$12B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
8%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$23.1B
|
CAGR 3-Years
24%
|
CAGR 5-Years
12%
|
CAGR 10-Years
13%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$3.6B
|
CAGR 3-Years
19%
|
CAGR 5-Years
22%
|
CAGR 10-Years
25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Liabilities
$3.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
13%
|
CAGR 10-Years
20%
|
|
Savara Inc
Glance View
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Austin, Texas and currently employs 22 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of aPAP. Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the build-up of surfactant in the alveoli or air sacs of the lungs.
See Also
What is Savara Inc's Total Current Liabilities?
Total Current Liabilities
12.8m
USD
Based on the financial report for Sep 30, 2024, Savara Inc's Total Current Liabilities amounts to 12.8m USD.
What is Savara Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
5%
Over the last year, the Total Current Liabilities growth was 42%. The average annual Total Current Liabilities growth rates for Savara Inc have been 6% over the past three years , 9% over the past five years , and 5% over the past ten years .
You don't have any saved screeners yet